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Abstract
Background: Medium chain acyl-CoA dehydrogenase deficiency (MCADD) is a disorder of mitochondrial fatty acid
oxidation and is one of the most common inborn errors of metabolism. Identification of MCADD via newborn
screening permits the introduction of interventions that can significantly reduce associated morbidity and mortality.
This study reports on the first three years of newborn screening for MCADD in Ontario, Canada.
Methods: Newborn Screening Ontario began screening for MCADD in April 2006, by quantification of
acylcarnitines (primarily octanoylcarnitine, C8) in dried blood spots using tandem mass spectrometry. Babies with
positive screening results were referred to physicians at one of five regional Newborn Screening Treatment
Centres, who were responsible for diagnostic evaluation and follow-up care.
Results: From April 2006 through March 2009, approximately 439 000 infants were screened for MCADD in
Ontario. Seventy-four infants screened positive, with a median C8 level of 0.68 uM (range 0.33-30.41 uM).
Thirty-one of the screen positive infants have been confirmed to have MCADD, while 36 have been
confirmed to be unaffected. Screening C8 levels were higher among infants with MCADD (median 8.93 uM)
compared to those with false positive results (median 0.47 uM). Molecular testing was available for 29
confirmed cases of MCADD, 15 of whom were homozygous for the common c.985A > G mutation. Infants
homozygous for the common mutation tended to have higher C8 levels (median 12.13 uM) relative to
compound heterozygotes for c.985A > G and a second detectable mutation (median 2.01 uM). Eight
confirmed mutation carriers were identified among infants in the false positive group. The positive predictive
value of a screen positive for MCADD was 46%. The estimated birth prevalence of MCADD in Ontario is
approximately 1 in 14 000.
Conclusions: The birth prevalence of MCADD and positive predictive value of the screening test were similar to
those identified by other newborn screening programs internationally. We observed some evidence of correlation
between genotype and biochemical phenotype (C8 levels), and between C8 screening levels and eventual
diagnosis. Current research priorities include further examining the relationships among genotype, biochemical
phenotype, and clinical phenotype, with the ultimate goal of improving clinical risk prediction in order to provide
tailored disease management advice and genetic counselling to families.
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Medium chain acyl-CoA dehydrogenase deficiency
(MCADD) is a disorder of mitochondrial fatty acid
oxidation and is one of the most common inborn errors
of metabolism. The majority of infants with this
condition are asymptomatic at birth. However, there is a
mortality rate of up to 25% during the first clinical pre-
sentation of an undiagnosed infant, which typically
occurs between three months and 3 years of age [1,2].
Identification of infants with MCADD via newborn
screening, prior to the onset of symptoms, permits the
introduction of interventions which can significantly
reduce associated morbidity and mortality in affected
infants [2].
Infants with MCADD have insufficient activity of the
enzyme required to catalyze the first step in the mito-
chondrial beta-oxidation pathway for medium-chain
fatty acids. This process is essential for energy produc-
tion and also for the formation of ketone bodies in the
liver. The latter provides an alternative energy source
during periods of increased metabolic demands or
reduced dietary intake. When faced with a physiological
stress such as an intercurrent illness, infants with
MCADD are unable to respond adequately to increased
energy demand, which may lead to symptomatic presen-
tation. Symptomatic presentation of MCADD is charac-
terized by an acute metabolic crisis, which typically
includes lethargy, vomiting, hypoketotic hypoglycemia,
and encephalopathy, and can progress to coma and
death. Historically, up to one third of survivors of a
metabolic crisis due to MCADD may experience some
developmental delay [1].
Infants confirmed to have MCADD are treated with
avoidance of fasting and aggressive intervention with
intravenous glucose when ill. The prognosis for infants
with MCADD is excellent once the diagnosis is estab-
lished [2,3]. In the published literature, reported deaths
after the diagnosis of MCADD have been rare and have
mainly occurred in children diagnosed late or in whom
early signs were unrecognized and/or intervention was
delayed [1,2,4-6].
Infants with undiagnosed MCADD who died prior to
a diagnosis being made have often been mislabelled as
having had sudden infant death syndrome, Reye syn-
drome, hepatitis, poisoning or unknown cause of death
[1]. Unless metabolic testing was conducted on an
autopsy specimen, these infants were never identified in
attempts to establish the incidence of MCADD [1].
Newborn screening for MCADD has yielded an interna-
tional birth prevalence of 1 in 14 600 based on the
screening of nearly 8.2 million newborns of mainly Eur-
opean descent [7]. This estimate is about two to three-
fold higher than the clinically estimated birth prevalence
of MCADD in the absence of screening [1,7] and likely
reflects both missed diagnoses of symptomatic cases,
and identification of asymptomatic cases through
screening that may have never come to clinical
attention.
The MCAD protein is produced by the ACADM gene
(chromosome 1p31). More than 30 mutations in this
gene have been identified; most of these are missense
mutations whereby one amino acid is substituted for
another [1,8]. The most frequent mutation is an adenine
to guanine transition at coding position 985 (c.985A >
G); this leads to a substitution of glutamate for lysine at
position 329 of the protein. About 80% of individuals of
European descent who are clinically diagnosed with
MCADD are homozygous for the common mutation
[1,8]. Newborn screening has revealed a more varied
mutation spectrum, with c.985A > G homozygotes
representing from 30% to 80% of MCADD cases [1,7].
Biochemically MCADD is characterized by elevated
medium-chain acylcarnitines in blood, particularly octa-
noylcarnitine (C8). It can be identified by screening of
dried blood spots via quantitative detection of acylcarni-
tines using tandem mass (MS/MS) spectrometry. Over
the past decade MCADD has been added to the panel
of diseases included in newborn screening programs in
many regions. Newborn Screening Ontario (NSO) began
screening for MCADD on April 5, 2006. Here we review
the birth prevalence of MCADD in the Ontario popula-
tion along with the biochemical and molecular charac-
teristics of confirmed cases and the positive predictive
value of the screening test.
Methods
Screening methodology
Dried blood spots were sent to Newborn Screening
Ontario from submitting centres (primarily hospitals)
across the province. The modal age at sample collection
was 25 hours and 95% of samples were collected before
4 1/3 days of age. Less than 1% of samples were col-
lected before 24 hours of age and a repeat sample was
requested in such cases. Following sample extraction
and butylation of amino acids and acylcarnitines, detec-
tion and quantitation of acylcarnitine butyl esters was
achieved by MS/MS using Waters Quattro Micro tan-
dem mass spectrometers in combination with Waters
1525 μ Binary HPLC Pump using a combination Multi-
ple Reaction Monitoring (MRM) and Parent ion scans
of 85 Da.
Screening for MCAD deficiency was accomplished
using C8 acylcarnitine (octanoylcarnitine) as a primary
analyte with C6 (hexanoylcarnitine), C10 (decanoylcarni-
tine) and C10:1 (decenoylcarnitine) acylcarnitines as sec-
ondary analytes. We also included two ratios in the
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ger levels used to flag samples as potentially screen posi-
tive was initially based on review of the data available in
the Region 4 Genetics Collaborative MS/MS data pro-
ject. From April 2006 through to September 2007, sam-
ples that had an elevation of any of the above analytes
or ratios were flagged in the information system as a
potential positive result, regardless of the concentration
of the primary C8 acylcarnitine analyte. The specific
logic to flag potential screen positive children was:
[C8 > 0.4 OR C6 > 0.24 OR C10:1 > 0.15 OR C10 > 0.3
OR C8/C2 > 0.01 OR C8/C10 > 2.5]. This resulted in a
very high number of results requiring manual review
during which only those samples with a C8 acylcarnitine
level exceeding its cutoff were designated as screen posi-
tive. The logic used to flag potential screen positive
results was therefore changed in September 2007 to
require an elevation of the C8 acylcarnitine thus redu-
cing the number of results being flagged by the informa-
tion system for review. Using the new logic, samples
with a C8 value in excess of 0.5 were flagged as poten-
tial screen positive irrespective of the results of any
o t h e ra n a l y t e so rr a t i o s ,b u ts a m p l e sw i t haC 8v a l u e
between 0.4 uM and 0.5 uM were flagged only if one or
more of the secondary analytes or ratios were also
above predetermined cut-off levels (using the same cut-
offs specified above), or if the newborn was older than
7 days of age at the time the screening sample was col-
lected. All flagged samples were repunched and re-ana-
lyzed in duplicate. Final results with a C8 acylcarnitine ≥
0.4 μmol/L with accompanying elevations of secondary
analytes (or age at collection greater than 7 days), or a C8
acylcarnitine ≥ 0.5 μmol/L in isolation generated a screen
positive result. The final decision regarding whether
these infants were designated as screen positive was
based on the determination of a biochemical geneticist
who reviewed all flagged results.
Diagnostic testing
Positive results were referred to one of five Newborn
Screening Treatment Centres across the province of
Ontario. These Centres, located at regional Pediatric
Academic Health Sciences Centres, are responsible for
coordinating diagnostic testing and follow-up care for
infants with positive newborn screening results in
Ontario. Diagnostic findings are then communicated
back to NSO. Criteria for the clinical diagnosis of
MCADD have evolved over time. Traditionally, demon-
stration of deficient enzymatic activity has been consid-
ered the gold standard for diagnosis of this condition,
however, it is now recognized that the high specificity of
a diagnostic plasma acylcarnitine profile, or the demon-
stration of homozygosity for the common c.985A > G
mutation, reduces the need to utilize an enzyme assay
for confirmation in a clinical setting [1]. Biochemical,
cellular and genotypic characterization of screen positive
cases varied amongst the Treatment Centres across the
province. In general, infants were classified as truly
affected by the responsible metabolic geneticist at each
of the Treatment Centres if they were confirmed to be
homozygous for the common MCADD mutation or
were a compound heterozygote and/or had abnormal
plasma acylcarnitines and/or urine organic acids on
diagnostic testing. Plasma acylcarnitine profiles were
considered abnormal if there was a persistent elevation
of C8 acylcarnitine with abnormal C8/C10 ratio. Diag-
nostic centres did not consistently require the elevation
of C10:1 acylcarnitine. Urine organic acids were consid-
ered abnormal if characteristic acylglycines were
detected or if there was increased excretion of medium
chain diacrboxylic acids and their metabolites. Diagnos-
tic centres did not consistently require the detection of
hexanoylglycine in the urine as a necessary diagnostic
criterion. To be classified as truly affected, it was
required that treatment be initiated, and that babies be
clinically followed, by a metabolic physician.
Results
Screen positive results
From April 5, 2006 to March 31, 2009, an estimated 439
000 infants were screened for MCADD by NSO.
Seventy-four infants screened positive. Forty of the
screen positives cases were male, 33 were female, and
one infant did not have sex specified on the newborn
screening requisition (Table 1). Approximately 80% of
screen positive infants were born after 37 weeks gesta-
tion. The mean birth weight was 2979 grams. Fifteen
percent of infants had a birth weight of less than 2500
grams. The majority of infants were reported to be
breast fed (75% exclusively, 10% partially) at the time of
the newborn screen (Table 1). The median C8 value for
screen positive cases was 0.68 uM (mean 4.29 uM,
range 0.33-30.41 uM). C8 screening values tended to be
lower for screen positive males (median 0.55 uM) com-
pared with females (median 1.40 uM) and for screen
positive preterm (median 0.49 uM) compared with
screen positive term (0.75 uM) infants (Table 1). The
sex difference was statistically significant (p < 0.05,
Wilcoxon Rank Sum test). All 74 screen positive infants
were referred to one of the five Newborn Screening
Treatment Centres for follow-up diagnostic testing and
care.
Follow-up results for screen positive cases
Thirty-one infants have been confirmed to have
MCADD and thirty-six infants have been found to be
unaffected, based on biochemical and/or molecular test-
ing coordinated at the regional Treatment Centres. The
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MCADD was 8.93 uM (mean 9.27 uM, range 0.84-30.4
uM), compared to a median C8 screening value of
0.47 uM (mean 0.50 uM, range 0.37-0.79) for infants
confirmed to be false positives. Males were overre-
presented among false positive cases, although the dif-
ference was not statistically significant (p > 0.05,
continuity-corrected chi-square test): 69% (25/36) of
infants with false positive results but only 45% (14/31)
of infants confirmed to have MCADD were male.
Results are unavailable for 7 infants who screened posi-
tive, either due to death prior to initiation of diagnostic
testing (mainly due to complications of prematurity) or
because a final diagnosis had not yet been established at
the time of this publication.
Molecular testing was performed on 29 of the 31 con-
firmed cases of MCADD. Molecular results were not
provided for 2 of the affected infants. Of the 29 infants
with MCADD who had molecular testing, 15 (52%)
were homozygous for the common c.985A > G muta-
tion, 5 (17%) were compound heterozygotes for c.985A
> G and a second mutation, 5 (17%) were presumed
compound heterozygotes for c.985A > G, however a sec-
ond mutation could not be identified despite clearly
abnormal biochemical findings, and 2 (7%) were com-
pound heterozygotes or were homozygous for other
abnormal alleles. The remaining 2 infants (7%) had
negative results for c.985A > G and no other mutations
were reported by the respective Treatment Centres.
Molecular testing results were also available for 8 of the
infants in the false positive group, who were confirmed
to be unaffected mutation carriers; among these infants,
5 were heterozygous for c.985A > G and 3 were hetero-
zygous for other abnormal alleles. These findings are
summarized in Table 2 along with the median and
mean C8 screening value for each group.
Based on the experience of Newborn Screening
Ontario, the positive predictive value of a screen positive
for MCADD was 46.3% (31/67) (excluding unresolved
cases). The estimated birth prevalence of this condition
in Ontario, based upon 3 years of newborn screening
data, is 1 in 14 157.
Discussion and conclusions
Our analysis of 3 years of data from Newborn Screening
Ontario, including approximately 439 000 infants
screened since the introduction of universal screening
for MCADD, has allowed us to establish the first evi-
dence based birth prevalence rate for MCADD in the
province of Ontario. The birth prevalence of 1 in 14 157
live births is in the range of that reported by other new-
born screening programs: for example. Rhead reported a
birth prevalence of 1 in 14 600 births based on the
results of an international survey of newborn screening
programs mainly in the US, Northern Europe, and Aus-
tralia [7]. Grosse and colleagues synthesized estimates
from the literature and estimated a frequency of from 1
in 10 000 to 1 in 27 000 among newborn screening
populations of European descent, with a lower frequency
in populations without European origin [1]. Horvath
recently reported a prevalence of 1 in 12 100 births
based on the newborn screening program in British
Columbia, Canada [9]. We observed a positive predictive
value of 46.3% for the screening test used in Ontario.
Rhead’s survey revealed a wide range of positive predic-
tive values for MCADD screening among newborn
screening programs internationally, with the majority of
programs reporting positive predictive values of 35% to
Table 1 Characteristics of infants who screened positive for MCADD
N (percent) Median C8
(uM)
Mean C8
(uM)
Sex (n = 73)*
Male 40 (55) 0.55 3.65
Female 33 (45) 1.40 5.18
Gestational age (n = 61)
< = 37 weeks 12 (20) 0.49 3.93
> 37 weeks 49 (80) 0.75 4.09
Birthweight (n = 65)
< 2500 grams 10 (15) 0.49 4.70
> = 2500 grams 55 (85) 0.62 3.70
Reported feeding status at time of screen (n = 63)
Breastfeeding 47 (75) 0.62 3.54
Partial breastfeeding 6 (10) 0.71 3.87
Formula or other (e.g., total parenteral nutrition) 10 (16) 0.94 5.98
* Note: sample sizes differ for sub-sample analyses because of missing data on the blood spot requisition forms (n = 74, median C8 0.68 uM, mean C8 4.29 uM,
range 0.33-30.41 uM)
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screening algorithms and cut-off values differ consider-
ably among programs.
Fifteen out of the 29 Ontario infants who were con-
firmed to have MCADD and underwent molecular test-
ing were homozygous for the common mutation
(c.985A > G). This represents 52% of the MCADD cases
in our population and is consistent with recent pub-
lished literature suggesting that typically about 40-50%
of the population of infants identified with MCADD via
newborn screening are homozygous for this mutation
[6,10-12], with a range of about 30-80% internationally
[1,7]. This compares with estimates that approximately
80% of those identified clinically are homozygous for
c.985A > G [1,8]. The C8 screening levels for children
with the common mutation in our study were elevated
compared to compound heterozygotes with one copy of
c.985A > G (both with and without a detectable second
mutation). This is also consistent with published data
from other newborn screening programs documenting a
relationship between genotype and biochemical pheno-
type, whereby homozygosity for c.985A > G has been
associated with more severe levels of biochemical mar-
kers relative to some other genotypes [6,7,9,11-13].
There is some additional evidence that individuals with
MCADD who are homozygous for c.985A > G may be
likely to experience more severe clinical symptoms than
those with some other genotypes (i.e., a correlation
between genotype and clinical phenotype) [6], but other
mutations thought to be equally severe have also been
identified [10]. There is considerable variability in clini-
cal presentation even among children who are homozy-
gous for the c.985A > G mutation, highlighting the
imperfect relationship between genotype and clinical
risk.
Eleven of the MCADD cases in whom mutation analy-
sis was performed were identified as compound hetero-
zygotes, of whom 10 were identified with one copy of
the c.985A > G mutation. In 5 of those infants, there
was no detectable second mutation. A total of 6 pre-
viously unreported mutations were identified among
screen positive infants (Table 2). Researchers have used
a variety of approaches to try to predict the biochemical
impact of rare or novel mutations in the ACADM gene
detected by newborn screening, including the applica-
tion of indirect criteria and computer-based modeling
techniques to assess the likely functional consequences
of particular types of mutations [11-13] and molecular
studies to evaluate impact on protein structure and
enzyme activity [14,15]. As described, there is also some
direct evidence of a relationship between genotype and
biochemical phenotype [11,13]. For example, Arnold
and colleagues identified a significant association
between predicted mutation severity (with severe muta-
tions including c.985A > G as well as deletions, non-
sense and splice site mutations) and levels of analytes
including C8 and the C8/C2 ratio [10] and Smith and
colleagues recently characterized a range of variants of
Table 2 Median and mean C8 screening value for confirmed cases and confirmed heterozygous carriers of MCADD by
genotype
N Median
Screening C8 (uM)
Homozygotes: c.985A > G 15 12.13
(mean 11.72, range 2.64-30.41)
Compound heterozygotes: c.985A > G, detectable 2
nd mutation 5 2.01
c.250C > T (mean 2.82, range 0.84-5.94)
c.388-5G > A
a
c.1073A > T
a
c.503A > C
a
IVS8-13A > G
a
Compound heterozygotes: c.985A > G, no detectable 2
nd mutation 5 2.69
(mean 6.14, range 0.86-13.69
Compound heterozygotes or homozygotes for other mutations 2 12.34
c.799G>A/c.85C > A (mean 12.34, range 0.88-23.80)
Homozygous for 3 bp deletion c.424-426delAAG
a
Heterozygous mutation carriers 8 0.50
c.985A > G (mean 0.52, range 0.44-0.70)
c.347G > A
c.430-432delAAG
a
c.583G > A
amutation is possibly novel
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parameters [13]. However, it is challenging to extrapo-
late from these results in order to predict clinical symp-
toms. For example, the c.199T > C mutation has been
widely reported in screen-identified cases of MCADD
but not in clinically diagnosed cases, and both in vitro
and in vivo studies suggest that it is predicted to be a
“mild” mutation; yet it cannot be ruled out as potentially
conferring risk of metabolic decompensation [11,12,14].
As noted above, testing for the common c.985A > G
was not performed on all screen positive children, nor
was sequencing or specific testing for the c.199T > C
mutation performed consistently in all presumed posi-
tive children. Despite this, and given that sequencing
was performed in at least 15 infants of the cohort, it is
unusual that no instances of the C.199T > C mutation
were detected. Environmental triggers (catabolic stress)
are clearly important influences on clinical risk, and
some have argued that there must be additional factors
(e.g., epigenetic influences, interactions with other
pathways) that complicate the relationship between gen-
otype, biochemical phenotype, and clinical presentation
[10,11].
Ontario infants confirmed to have MCADD had
markedly elevated C8 levels compared to those desig-
nated as false positives (median C8 levels of 8.93 uM
versus 0.47 uM respectively), including those determined
to be heterozygous mutation carriers (median C8 level
of 0.5 uM). Eight carriers were identified in the false
positive group in our study, for a carrier frequency in
t h a tg r o u po fa tl e a s t2 2 %( 8 / 3 6 ) ,m u c hh i g h e rt h a n
w o u l db ee x p e c t e di nt h eg e n e r a lp o p u l a t i o n .O t h e r
authors have also noted that individuals who are non-
affected heterozygous MCADD mutation carriers have
higher C8 levels than those with no mutations and they
are thus overrepresented among infants with false posi-
tive newborn screening results [6,16,17]. Setting a cut-
off for disease detection that maximizes sensitivity while
minimizing false positive results and the detection of
carriers is challenging. There is considerable variation
across existing newborn screening programs with
respect to the analytes, cut-offs, and algorithms used in
screening for MCADD [7]. While there is some evidence
that neonatal levels of C8 and other analytes may be
predictive of clinical severity among infants diagnosed
with MCADD [6,10], again the documented variability
in clinical presentation does not allow for precise
prediction. Thus, all infants with a confirmed diagnosis
of MCADD are considered at risk and require close
monitoring and preventive measures to avoid catabolic
stress [10].
Finally, a further diagnostic challenge relates to those
infants identified with only one mutation and with
slightly abnormal biochemical results. This contributes
to final results being unavailable for some screen posi-
tive infants, as noted above. It is unclear if such infants
have a mild form of MCADD or are simply carriers.
Enzymology studies are typically considered the gold
standard to resolve these cases, however, the results of
such studies often fail to provide the desired clarifica-
tion. Collectively, the challenges we have described in
defining and diagnosing MCADD in terms of predicting
clinical risk (e.g., with respect to uncertainty of geno-
type-phenotype correlations, variability in presentation
even among known “severe” mutations, and the exis-
tence of unresolvable or borderline cases based on mar-
ginal biochemistry and an inability to detect two
mutations) present barriers to the provision of clear
medical guidance and genetic counselling to families. A
limitation of the data presented in this paper is the lack
of consistency in the biochemical definition of MCADD
applied at the various diagnostic centres. While all
babies classified in the paper as being truly affected
were being treated and followed clinically, the potential
that some may not truly be at risk for a metabolic
decompensation due to MCADD exists. This clinical
judgement must be made with consideration to the
available measures to completely rule out risk. It has
been proposed that elevation of urinary hexanoylglycine
is a necessary diagnostic parameter to confirm a diagno-
sis of MCADD in screen positive infants [11,13,18]. This
was not specifically sought in the majority of infants in
t h i sc o h o r t .O fn o t e ,1 0o ft h e1 5i n f a n t sf o u n dt ob e
homozygous for the common c.985A > G mutation had
qualitative urine organic acids examined. Of these 10,
4 were reported as normal and specific mention of
elevated hexanoylglycine was made in only 2 patients;
this supports the observation previously reported that
routine organic acid analysis may not detect more subtle
elevations of hexanoylglycine that may be of clinical
significance [19,20]. The harmonization of diagnostic
evaluation practices amongst the diagnostic treatment
centres is a specific program m a t i cp r i o r i t yi nO n t a r i o .
Furthermore, the development of improved clinical risk
prediction data for infants with MCADD is a clear
research priority.
Additional limitations to th i sa n a l y s i sr e l a t et ot h e
inability to ascertain whether all identified screen posi-
tive individuals include all children with MCADD.
While a provincial feedback system currently exists for
outside centres to notify NSO of any new MCADD
diagnoses that were not identified by screening, the
effectiveness of this system remains uncertain. In the
absence of this information we cannot provide data on
the negative predictive value and the specificity and sen-
sitivity of the screening tests; to date no missed case has
been reported. An additional limitation resulting in the
incomplete characterization of the screened population
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NSO refers screen positive infants to one of five regional
Treatment Centres across the province. Variation exists
both amongst and within Treatment Centres with
regard to i) clinical follow-up testing performed and ii)
the level of detail in the results reported back to NSO.
A related issue is that while the current clinically driven
model of follow-up testing ensures appropriate medical
supervision of the infant’s diagnostic evaluation, it limits
the ability to address a number of relevant research
questions. A more standardized provincial approach to
follow-up is being considered for MCADD, and other
diseases targeted by newborn screening, to ensure con-
sistency in the clinical evaluation of screen positive
infants.
Evaluating the long-term effectiveness of newborn
screening for MCADD is challenging because simple
comparisons of outcomes in screened and unscreened
populations do not account for the differences in the
spectrum of disease severity. The prevalence of
MCADD is higher in screened populations and the dis-
tribution of genotypes also differs, suggesting that
cohorts of infants identified with MCADD based on
clinical symptoms (i.e., metabolic decompensation)
include more severe cases than cohorts of infants with
MCADD identified by newborn screening. The best
available evidence for screening effectiveness to date
comes from a large Australian study that compared
deaths and severe episodes in screened and unscreened
cohorts [2]. The researchers assumed that the actual
(rather than detected) prevalence of MCADD in the
unscreened group was similar to that observed in the
screened group (i.e., they accounted for underdiagnosis
in the unscreened population), and they demonstrated
that under reasonable assumptions about clinical risk
among undetected cases in the unscreened group, new-
born screening for MCADD led to a significant reduc-
tion in deaths and severe episodes of decompensation
[2]. While cost-effectiveness was not evaluated in this
study most studies have concluded that screening is
cost-effective relative to other health care interventions
[21-23]. However, based on the results of the aforemen-
tioned Australian cohort study [2], which identified a
lower than expected risk of long-term neurologic seque-
lae among surviving children and a smaller reduction in
mortality than has often been assumed based on screen-
ing, some previous cost-effectiveness analyses may have
overestimated the clinical benefit of newborn MCADD
screening [24].
We have described the results of the first three years
of newborn screening for MCADD by Newborn Screen-
ing Ontario. The birth prevalence of the disease and
positive predictive value of the screening test were simi-
lar to those identified by other programs internationally.
We observed some evidence of correlation between gen-
otype and biochemical phenotype but we faced diagnos-
tic challenges with some cases involving new mutations
and/or borderline biochemical results. The clinical effec-
tiveness of newborn screening for MCADD is relatively
well established [2]. Current research priorities in the
field include further examining the relationships among
genotype, biochemical phenotype, and clinical pheno-
type, with the ultimate goal of improving clinical risk
prediction so that disease management advice and
genetic counselling can be better tailored to meet the
needs of individual families.
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